NYSE: AORT | Healthcare / Medical Devices & Instruments / USA |
17.74 | +0.1400 | +0.80% | Vol 220.98K | 1Y Perf 37.61% |
Nov 30th, 2023 16:00 DELAYED |
BID | 17.02 | ASK | 17.90 | ||
Open | 17.76 | Previous Close | 17.74 | ||
Pre-Market | - | After-Market | 17.90 | ||
- - | 0.16 0.90% |
Target Price | 23.13 | Analyst Rating | Strong Buy 1.20 | |
Potential % | 30.38 | Finscreener Ranking | ★★★+ 50.85 | |
Insiders Trans % 3/6/12 mo. | -/-100/-56 | Value Ranking | ★★★+ 52.85 | |
Insiders Value % 3/6/12 mo. | -/-100/-57 | Growth Ranking | ★ 38.34 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-100/-54 | Income Ranking | — - | |
Price Range Ratio 52W % | 96.50 | Earnings Rating | — | |
Market Cap | 728.20M | Earnings Date | 2nd Nov 2023 | |
Alpha | -0.02 | Standard Deviation | 0.13 | |
Beta | 1.41 |
Today's Price Range 17.4717.87 | 52W Range 11.3917.97 | 5 Year PE Ratio Range -259.50684.30 |
Summary:
Buy
Technical Indicators: | Buy |
Moving Averages: | Strong Buy |
Performance | |||
---|---|---|---|
1 Week | 0.45% | ||
1 Month | 37.73% | ||
3 Months | 1.90% | ||
6 Months | 20.11% | ||
1 Year | 37.61% | ||
3 Years | -15.24% | ||
5 Years | -41.49% | ||
10 Years | 60.54% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -2.04 | |||
ROE last 12 Months | -15.88 | |||
ROA (5Y Avg) | -0.72 | |||
ROA last 12 Months | -5.74 | |||
ROC (5Y Avg) | 0.60 | |||
ROC last 12 Months | -4.88 | |||
Return on invested Capital Q | -1.49 | |||
Return on invested Capital Y | -2.57 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 4.10 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-12.00 | ||||
1.97 | ||||
2.13 | ||||
324.40 | ||||
-35.60 | ||||
-0.11 | ||||
-3.16 | ||||
6.33 | ||||
820.19M | ||||
Forward PE | - | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
2.20 | ||||
5.20 | ||||
0.58 | ||||
1.39 | ||||
-1.10 | ||||
Leverage Ratio | 2.80 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
64.70 | ||||
-5.60 | ||||
1.70 | ||||
-5.40 | ||||
-9.11 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
234.39M | ||||
5.81 | ||||
3.00 | ||||
9.55 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2023 | 0.01 | 0.02 | 100.00 |
Q02 2023 | 0.01 | 0.06 | 500.00 |
Q01 2023 | -0.03 | 0.02 | 166.67 |
Q04 2022 | -0.17 | 0.10 | 158.82 |
Q03 2022 | -0.11 | -0.05 | 54.55 |
Q02 2022 | 0.04 | -0.03 | -175.00 |
Q01 2022 | 0.00 | 0.03 | - |
Q04 2021 | -0.11 | 0.00 | 100.00 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
Next Report Date | - |
Estimated EPS Next Report | 0.01 |
Estimates Count | 1 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 220.98K |
Shares Outstanding | 41.05K |
Shares Float | 38.34M |
Trades Count | 3.65K |
Dollar Volume | 3.91M |
Avg. Volume | 248.43K |
Avg. Weekly Volume | 283.29K |
Avg. Monthly Volume | 240.68K |
Avg. Quarterly Volume | 221.31K |
Artivion Inc. (NYSE: AORT) stock closed at 17.74 per share at the end of the most recent trading day (a 0.8% change compared to the prior day closing price) with a volume of 220.98K shares and market capitalization of 728.19M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 1200 people. Artivion Inc. CEO is James Patrick Mackin.
The one-year performance of Artivion Inc. stock is 37.61%, while year-to-date (YTD) performance is 46.37%. AORT stock has a five-year performance of -41.49%. Its 52-week range is between 11.39 and 17.97, which gives AORT stock a 52-week price range ratio of 96.50%
Artivion Inc. currently has a PE ratio of -12.00, a price-to-book (PB) ratio of 1.97, a price-to-sale (PS) ratio of 2.13, a price to cashflow ratio of 324.40, a PEG ratio of -, a ROA of -5.74%, a ROC of -4.88% and a ROE of -15.88%. The company’s profit margin is -9.11%, its EBITDA margin is 1.70%, and its revenue ttm is $234.39 Million , which makes it $5.81 revenue per share.
Of the last four earnings reports from Artivion Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.01 for the next earnings report. Artivion Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Artivion Inc. is Strong Buy (1.2), with a target price of $23.13, which is +30.38% compared to the current price. The earnings rating for Artivion Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Artivion Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Artivion Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 41.65, ATR14 : 0.74, CCI20 : 118.27, Chaikin Money Flow : 0.03, MACD : 1.00, Money Flow Index : 77.94, ROC : 33.08, RSI : 73.30, STOCH (14,3) : 96.82, STOCH RSI : 0.64, UO : 62.80, Williams %R : -3.18), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Artivion Inc. in the last 12-months were: Amy D. Horton (Option Excercise at a value of $212 101), Amy D. Horton (Sold 22 645 shares of value $315 694 ), Andrew M. Green (Sold 1 747 shares of value $22 603 ), D. Ashley Lee (Option Excercise at a value of $377 057), D. Ashley Lee (Sold 36 395 shares of value $480 542 ), David Ashley Lee (Option Excercise at a value of $377 057), David Ashley Lee (Sold 34 994 shares of value $461 904 ), Dennis B Maier (Sold 2 330 shares of value $30 146 ), Getz Matthew (Sold 8 631 shares of value $130 622 ), Green Andrew (Sold 2 572 shares of value $33 669 ), Horton Amy (Option Excercise at a value of $212 101), Horton Amy (Sold 20 121 shares of value $281 366 ), James P. Mackin (Option Excercise at a value of $671 222), James P. Mackin (Sold 89 120 shares of value $1 173 728 ), James Patrick Mackin (Option Excercise at a value of $671 222), James Patrick Mackin (Sold 79 130 shares of value $1 039 994 ), Jean F. Holloway (Sold 2 867 shares of value $37 521 ), John E. Davis (Option Excercise at a value of $89 549), John E. Davis (Sold 3 514 shares of value $45 993 ), Maier Dennis (Sold 19 705 shares of value $293 408 ), Maney Rochelle (Sold 2 105 shares of value $27 746 ), Marshall S. Stanton (Sold 2 337 shares of value $30 236 ), Matthew A. Getz (Sold 1 600 shares of value $20 701 ), Rochelle L. Maney (Sold 1 284 shares of value $16 733 ), Stanton Marshall (Sold 3 244 shares of value $42 404 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Cryolife Inc is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures focused on aortic repair. The company has two reportable segments namely Medical devices and Preservation Services. The Medical Devices segment includes revenues from sales of BioGlue, On-X products, JOTEC products, CardioGenesis cardiac laser therapy, PerClot, and PhotoFix. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular tissues. It generates a majority of its revenue from the Medical Devices segment. Geographically, the company generates a majority of its revenue from the United States.
CEO: James Patrick Mackin
Telephone: +1 770 419-3355
Address: 1655 Roberts Boulevard North West, Kennesaw 30144, GA, US
Number of employees: 1 200
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.